Annexon Inc (ANNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Annexon Inc (ANNX) has a cash flow conversion efficiency ratio of -0.229x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.80 Million) by net assets ($204.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ANNX net asset quality index to measure how much of total assets are equity-financed.
Annexon Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Annexon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Annexon Inc (ANNX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Annexon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annexon Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TeamViewer AG
F:TMV
|
0.803x |
|
PennyMac Mortgage Investment Trust
NYSE:PMT
|
-0.688x |
|
Standard Foods Corp
TW:1227
|
0.063x |
|
Abacus Global Management, Inc.
NYSE:ABX
|
0.217x |
|
Chengdu Kanghua Biological Products
SHE:300841
|
0.026x |
|
Mersen SA
PA:MRN
|
0.136x |
|
Beijing Haitian Ruisheng Science Technology Ltd
SHG:688787
|
0.019x |
|
BioAge Labs, Inc
NASDAQ:BIOA
|
-0.058x |
Annual Cash Flow Conversion Efficiency for Annexon Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Annexon Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Annexon Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $211.65 Million | $-186.36 Million | -0.880x | -118.70% |
| 2024-12-31 | $293.11 Million | $-118.01 Million | -0.403x | +16.73% |
| 2023-12-31 | $250.56 Million | $-121.14 Million | -0.483x | +3.89% |
| 2022-12-31 | $231.19 Million | $-116.31 Million | -0.503x | -9.95% |
| 2021-12-31 | $231.91 Million | $-106.11 Million | -0.458x | -196.73% |
| 2020-12-31 | $344.28 Million | $-53.09 Million | -0.154x | +76.33% |
| 2019-12-31 | $43.53 Million | $-28.36 Million | -0.651x | -43.56% |
| 2018-12-31 | $37.88 Million | $-17.19 Million | -0.454x | -208.88% |
| 2017-12-31 | $-46.21 Million | $-19.26 Million | 0.417x | -- |
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase… Read more